NCT02703194View on ClinicalTrials.gov

Leflunomide for Maintenance of Remission in IgG4 Related Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Immunoglobulin G4 Related Sclerosing Disease
Interventions
DRUG

Prednisone

Prednisone:A starting dose of 0. 5-0. 8mg/(kg\*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.

DRUG

Leflunomide

Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).

Trial Locations (1)

100000

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER

NCT02703194 - Leflunomide for Maintenance of Remission in IgG4 Related Disease | Biotech Hunter | Biotech Hunter